<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913002</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-109-NRM</org_study_id>
    <secondary_id>LX4211.109</secondary_id>
    <nct_id>NCT01913002</nct_id>
  </id_info>
  <brief_title>Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Positive-controlled, 4-period, 4-way Crossover Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 800 mg and 2000 mg Compared With Placebo and Open-label Moxifloxacin in Healthy Subjects: A Thorough QT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000
      mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QTc intervals</measure>
    <time_frame>Day -1, Day 1 of each period (2, 3, 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing an adverse event</measure>
    <time_frame>up to 87 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LX4211</measure>
    <time_frame>Day 1 of each Period: predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing time on Day 1 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LX4211 800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LX4211 2000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>moxifloxacin 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 800 mg</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 2000 mg</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin 400 mg</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211 Placebo</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects ≥18 to ≤55 years of age

          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140
             mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm

          -  Body mass index (BMI) ≥18 and ≤35 kg/sq m

          -  Able and willing to provide written informed consent

          -  Nonsmoker and has not used any tobacco products for at least 3 months prior to
             Screening

          -  Willing to adhere to the prohibitions and restrictions specified in this protocol

          -  Able to tolerate prolonged periods of quiet, motionless, supervised rest

        Exclusion Criteria:

          -  Use of any medication (prescription, over-the-counter, herbal tea, or supplements)
             within 5 days of dosing

          -  Use of any investigational agent or study treatment within 30 days prior to Screening

          -  Use of any protein or antibody-based therapeutic agents within 3 months prior to
             Screening

          -  Prior exposure to LX4211

          -  Daily use of cigarettes or any tobacco products within 3 months prior to Screening and
             while participating in the study

          -  History of any major surgery within 6 months prior to Screening

          -  History of any serious adverse reaction or hypersensitivity to any inactive component
             of LX4211

          -  History of renal disease or significantly abnormal kidney function tests

          -  History of hepatic disease or significantly abnormal liver function tests

          -  Women who are breastfeeding or are planning to become pregnant during the study

          -  History of any active infection within 14 days prior to Screening

          -  History of alcohol or substance abuse within 2 years prior to Screening

          -  History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1
             or HIV-2

          -  Presence of clinically significant physical, laboratory, or ECG findings (eg, QTcF
             &gt;450 msec for females and QTcF &gt;430 msec for males) at Screening

          -  &gt;30 premature ventricular beats per hour on the telemetry ECG monitoring at Day -2 of
             Period 1

          -  History of additional risk factors for the presence of a family history of Short QT
             Syndrome, Long QT Syndrome, sudden unexplained death at a young age (&lt;=40 years),
             drowning or sudden infant death syndrome in a first degree relative (ie, biological
             parent, sibling, or child)

          -  Any skin condition likely to interfere with ECG electrode placement or adhesion

          -  Any skin condition likely to interfere with ECG electrode placement or adhesion

          -  Donation or loss of &gt;400 mL of blood or blood product within 3 months prior to
             Screening

          -  Positive urine glucose during Screening

          -  Positive pregnancy test during Screening

          -  Positive urine screen for drugs of abuse during Screening

          -  Positive urine test for alcohol during Screening

          -  Inability or difficulty swallowing whole tablets or capsules

          -  Unable or unwilling to communicate or cooperate with the Investigator for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikenna (Ike) Ogbaa, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2013</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

